research Efficacy of Clinical and Pathogenetic Treatment of Patients with Alopecia Areata Associated with Metabolic Syndrome
The study evaluated a complex treatment method for alopecia areata (AA) associated with metabolic syndrome (MS) in 59 patients, focusing on correcting dyslipidaemia and insulin resistance. Patients were divided into four groups, receiving various combinations of basic therapy, rosuvastatin, thioctacid, and dietary adjustments. Results showed that group 1C, which received both rosuvastatin and thioctacid, had the most significant improvements in metabolic indicators and the highest rates of clinical recovery after 6 and 12 months. The study concluded that the pathogenetically substantiated treatment method effectively improved outcomes for patients with AA and MS.
